| 摘要 |
FIELD: medicine, pharmaceutics.SUBSTANCE: claimed is liquid composition of elsamitrucin for treatment of tumorour diseases or conditions, including: a) at least one stable salt of elsamitrucin, which represents product of free elsamitrucin base and organic acid and can exist as stable solid substance and does not include pseudo-salts or salts, obtained in situ, which exist only in solution, and b) pharmaceutically acceptable carrier, and claimed liquid composition does not contain antioxidants or methanol, ethanol, chloroform, n-butanol or t-butanol as admixtures, and claimed stable salt of elsamitrucin preserves at least 90% of its anti-tumor activity within 18 months in liquid form at appropriate storage temperature.EFFECT: it is shown, that compositions, namely disclosed in claimed invention water solutions of true elsamitrucin salts, can be preserved and introduced without reduction before application.16 cl, 7 dwg, 7 ex |
